Scientists are developing a ‘groundbreaking’ lung cancer vaccine which research suggests will be effective in preventing up to 90 per cent of cases.
The jab — which will be given to those at highest risk of developing the disease — will train the immune system to spot and attack early signs of disease.
Experts described it as a ‘crucial moment’ in the fight against the devastating disease, which affects 48,500 in the UK every year.
Known as ‘LungVax’, it is being created by the University of Oxford, the Francis Crick Institute and University College London.
Lung cancer cells look different from normal cells due to having ‘red flag’ proteins called neoantigens.
The jab — which will be given to those at highest risk of developing the disease — will train the immune system to spot and attack early signs of disease. Experts described it as a ‘crucial moment’ in the fight against the devastating disease, which affects 48,500 in the UK every year
Your browser does not support iframes.
Your browser does not support iframes.
Neoantigens appear on the surface of the cell because of cancer-causing mutations within the cell’s DNA.
The LungVax vaccine will carry a strand of DNA which trains the immune system to recognise these neoantigens on abnormal lung cells.
It will then activate the immune system to kill these cells and stop lung cancer.
Professor Tim Eilliot, lead researcher at the University of Oxford, said: ‘Cancer is a disease of our own bodies and it’s hard for the immune system to distinguish between what’s normal and what’s cancer.
‘Getting the immune system to recognise and attack cancer is one of the biggest challenges in cancer research today.
‘This research could deliver an off-the-shelf vaccine based on Oxford’s vaccine technology, which proved itself in the Covid pandemic.
‘If we can replicate the kind of success seen in trials during the pandemic, we could save the lives of tens of thousands of people every year in the UK alone.’
Researchers have been granted up to £1.7 million from Cancer Research UK and the CRIS Cancer Foundation.
The team will receive funding for the study over the next 2 years to support lab research and initial manufacturing of 3,000 doses of the vaccine at the Oxford Clinical BioManufacturing Facility.
Symptoms of lung cancer are often not noticeable until the cancer has spread through the lungs, to other parts of the body
Your browser does not support iframes.
While the level of progress for cancer survival for some forms of the disease has been rapid, such as for breast and prostate cancers, others, like those for lung and pancreas have only improved at a snail’s pace
If successful, the vaccine will move straight into a clinical trials, involving those at biggest risk of disease, such as current and former smokers who currently qualify for targeted lung health checks in some parts of the UK.
Fewer than 10 per cent of people with lung cancer survive their disease for 10 years or more.
Professor Mariam Jamal-Hanjani of University College London and the Francis Crick Institute, said: ‘We think the vaccine could cover around 90 per cent of all lung cancers, based on our computer models and previous research, and this funding will allow us to take the vital first steps towards trials in patients.
‘LungVax will not replace stopping smoking as the best way to reduce your risk of lung cancer.
‘But it could offer a viable route to preventing some of the earliest stage cancers from emerging in the first place.’
Lola Manterola, President of CRIS Cancer Foundation, said: ‘We are at a crucial moment in the history of cancer research and treatment.
‘For the first time, technology and knowledge of the immune system are allowing us to take the first steps towards preventing cancer.
‘This groundbreaking study represents a firm step in that direction, and we at CRIS consider it essential to support it.’
